Since being officially condoned by the FDA in 2013, Risk-Based Monitoring (RBM) has progressed to become a viable clinical monitoring technique, leveraging the latest technology to proactively identify challenges to trial safety, data analysis, and compliance. With clinical trial resources prioritized by risk, RBM has brought study sponsors, CROs, and other stakeholders greater oversight into how trials are conducted.

But could there be a better pathway for RBM – a more strategic approach that can optimize monitoring in real time?

In our webinar – Revolutionizing Risk-Based Monitoring Through Real-Time Analytics – Biorasi will discuss a more sophisticated methodology for addressing RBM throughout the clinical trial, focusing on:

• Pros and cons of different approaches to integrate risk assessment into clinical monitoring – risk-based monitoring being one of the most advanced approaches.
• The importance of electronic data collection and real-time analytics in informing risk-based monitoring.
• How to optimize data intelligence for full clinical trial transparency and visibility.
• Using real-world examples to show how risk-based monitoring coupled with analytics empowers clinical study stakeholders.